Skip to main content

Table 1 Characteristics of the 41 patients with PsA and obesity included in the study

From: Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study

  Number (%) or median (IQR)
Sex women/men, n (%) 26 (63.4)/15 (36.6)
Age, years 54 (48.5–62)
Duration of psoriasis, years 32 (19–40)
Duration of PsA symptoms, years 17 (11–27)
PsA type, n (%)
 Peripheral disease 35 (85)
 Axial disease 2 (5)
 Combination peripheral/axial 4 (10)
History of dactylitis, n (%) 21 (51)
History of anterior uveitis, n (%) 3 (7)
NSAIDs, n (%) 27 (66)
TNFi all, n (%) 15 (37)
 TNFi in monotherapy 4
 TNFi + csDMARD 11
Ustekinumab monotherapy, n (%) 1 (2.4)
csDMARD without biologic, n (%) 19 (46)
 Methotrexate 13
 Sulfasalazine 2
 Apremilast 1
 Methotrexate + sulfasalazine 3
Anti-hypertensives, n (%) 18 (44)
Lipid lowering therapy, n (%) 6 (15)
Oral anti-diabetics, n (%) 1 (2.4)
  1. csDMARD conventional synthetic disease modifying anti-rheumatic drug, NSAID non-steroidal anti-inflammatory drug, TNFi tumour necrosis factor inhibitor